Drugs / ZL-1310
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT07531095 | Apr 2026 → May 2028 expected | small cell lung carcinoma | Amgen | Recruiting | No outcome recorded |
| Phase 1 | NCT06179069 | Jan 2024 → May 2027 expected | small cell lung carcinoma | Zai Lab (Shanghai) Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT07707895 | Aug 2026 → Apr 2030 expected | pulmonary large cell neuroendocrine carcinoma, small cell lung carcinoma | Boehringer Ingelheim | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT06885281 | May 2025 → Aug 2027 expected | cancer | Zai Lab (Shanghai) Co., Ltd. | Recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07218146 | Nov 2025 → Jun 2028 expected | small cell lung carcinoma | Zai Lab (Shanghai) Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ZL-1310 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06179069 ↗ |
| Modality | Other / unclassified | “ZL-1310, a DLL3 Antibody-Drug Conjugate (ADC)” NCT07218146 ↗ |
| Route | Intravenous | “administered intravenously” NCT06885281 ↗ |